ScholarIQanswers from OpenAlex & ORCID
Francisco J. Blanco
ResearcherPublications, citations & collaboration network
Francisco J. Blanco is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Francisco J. Blanco have?
ScholarIQindexed works
Francisco J. Blanco has 1,168 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Francisco J. Blanco have?
ScholarIQcitation count
Francisco J. Blanco has 30,458 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Francisco J. Blanco?
ScholarIQh-index
Francisco J. Blanco has an h-index of 82 in OpenAlex.
What is the i10-index of Francisco J. Blanco?
ScholarIQi10-index
Francisco J. Blanco has an i10-index of 408 in OpenAlex.
What is the ORCID of Francisco J. Blanco?
ScholarIQorcid
The ORCID for Francisco J. Blanco is on the source record.
What is the OpenAlex record for Francisco J. Blanco?
ScholarIQopenalex
The OpenAlex for Francisco J. Blanco is on the source record.
What are the most-cited papers on Francisco J. Blanco?
ScholarIQmost cited works
OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis
Raveendhara R. Bannuru, Mikala C. Osani, Elizaveta E. Vaysbrot, N K Arden, Kim L. Bennell, S. Bierma-Zeinstra, Virginia B. Kraus, Stefan Lohmander, J. Haxby Abbott, M. Bhandari, Francisco J. Blanco, R. Espinosa, I.K. Haugen, Jianhao Lin, Lisa A. Mandl, Eeva Moilanen, Norimasa Nakamura, Lynn Snyder‐Mackler, Thomas H. Trojian, Martin Underwood, Timothy E. McAlindon
Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use
Virginia B. Kraus, Francisco J. Blanco, Martin Englund, M.A. Karsdal, Stefan Lohmander
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd‐Ruediger Burmester, David Adams, Lisa Kerr, Chin Lee, Catherine L Shuler, Mark C. Genovese, Khalid Ahmed, Jeffrey Alper, N Barkham, Ralph E. Bennett, Francisco J. Blanco, Ricardo Blanco Alonso, Howard Blumstein, Michael S. Brooks, Gerd‐Rüdiger Burmester, Patricia Cagnoli, Paul H. Caldron, Alain Cantagrel, Der‐Yuan Chen, Melvin Churchill, Christine E. Codding, Benard Combe, Peter M.G. Deane, José Del Giudice, Atul Deodhar, Rajat K. Dhar, Eva Dokoupilová, Rita M. Egan, Andrea Everding, E. Galíndez, Mark C. Genovese, David H. Goddard, Alice B. Gottlieb, Philippe Goupille, Robert Griffin, Ramesh C. Gupta, Stephen Hall, Kalpita Hatti, Mary P. Howell, Yu‐Huei Huang, Ramina Jajoo, Namieta M. Janssen, Uta Kiltz, Alan Kivitz, Steven J. Klein, Mariusz Korkosz, Roshan Kotha, Joel M. Kremer, C Lue, José Luís Marenco de la Fuente, Helena Marzo‐Ortega, Jordi Gratacós Masmitja, Philip J. Mease, Pier Luigi Meroni, Eric C. Mueller, Anupama Nandagudi, Peter Nash, Antonio Fernández‐Nebro, C. Michael Neuwelt, Ana‐Maria Orbai, Meera R. Oza, Deborah L. Parks, Debendra Pattanaik, Maria Rell‐Bakalarska, David Rosmarin, Euthalia Roussou, Anna I. Rychlewska-Hanczewksa, David Sikes, Michael T. Stack, Prashanth Sunkureddi, Hasan Tahir, Diamant Thaçi, Tsen‐Fang Tsai, Anthony Turkiewicz, L. Unger, Raúl Veiga Cabello, Ulf Wagner, Cheng-Chung Wei, Alvin F. Wells, Peter Youssef, Agnieszka Zielińska
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley, C. Birbara, Janusz Jaworski, Jacob Aelion, Randall M. Stevens, Adele R. Vessey, Xiaojiang Zhan, Paul Bird